In the Margins

Sequoia's Valeant bet hard lesson for investors

March 29, 2016

By MarketWatch

Sequoia Fund investors learned a hard lesson when the fund's investment in Valeant Pharmaceuticals went bad last year. "Bad doesn’t even begin to describe the situation for Sequoia, one of the most legendary mutual funds, which has seen its reputation torched by a bad bet on a controversial stock," writes MarketWatch's Chuck Jaffe in his latest column. Robert Goldfarb, CEO of adviser Ruane, Cunniff & Goldfarb and co-manager of Sequoia, resigned his fund duties last Wednesday. Read the original column from MarketWatch

 

 

Most Read

10 Things
10 Things...on the regulatory agenda

The Securities and Exchange Commission has been accused of "over-regulation" in recent years as it has proposed and finalized dozens of rules in a relatively short ...

10 Things
10 Things...to read in summer 2024

It's the Summer Solstice, and that means that for most of us the sun is shining, temperatures are heating up, and longer days allow for pursuits ...